

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Phase III investigation of selinexor in combination with bortezomib/dexamethasone revealed which of the following Grade 3/4 adverse events to be most commonly associated with this regimen?**
 - Hypophysitis
 - Peripheral neuropathy
 - Pneumonitis
 - Rash
 - Thrombocytopenia
- Which of the following CAR T-cell agents is directed against BCMA?**
 - Axicabtagene ciloleucel
 - Brexucabtagene autoleucel
 - Ciltacabtagene autoleucel
 - Lisocabtagene maraleucel
- The Phase III MAIA trial demonstrated significant 5-year progression-free and overall survival benefits with daratumumab in which of the following settings?**
 - Newly diagnosed, transplant ineligible
 - Relapsed/refractory, high-risk cytogenetics
 - After at least 4 prior lines of therapy
 - After ASCT as maintenance therapy
- Which of the following agents is an inhibitor of XPO1, which is overexpressed in multiple myeloma (MM) and correlates with poor outcomes?**
 - Mezigidomide
 - Daratumumab
 - Isatuximab
 - Selinexor
- The KarMMa study of idecabtagene vicleucel (ide-cel) for relapsed/refractory (R/R) MM demonstrated which of the following clinical outcomes?**
 - A high (>70%) overall response rate
 - A high rate of severe (Grade ≥ 3) neurotoxic events
 - Both a and b
 - Neither a nor b